The AI Company That Warns AI Is Dangerous Now Wants to Cure Disease, and It Launched a Drug Lab Right Before Its IPO

Anthropic unveiled Claude Science, a dedicated AI workbench that gives researchers one place to do computational science instead of juggling databases and pipelines all day. It plugs into more than 60 scientific databases, ships with toolkits for genomics, protein structure and chemistry, and puts an AI assistant at the center that acts like a project manager, organizing whole projects and delegating to sub-assistants. On the tooling alone, this is genuinely useful, and researchers quoted at launch seem to mean it.

Then came the swing for the fences. Anthropic is also starting its own internal drug discovery program, aimed, admirably, at neglected diseases that big pharma finds unprofitable, and CEO Dario Amodei keeps talking about compressing life sciences R&D by a factor of ten. That is a spectacular promise from a company whose other favorite talking point is how dangerous AI could become. Save the world and warn about the world, on the same stage.

And the timing writes its own caption. This lands as Anthropic races toward a blockbuster IPO, right after it hired AlphaFold Nobel laureate John Jumper and bought Coefficient Bio. Curing neglected diseases is a beautiful mission and also, conveniently, a fresh enterprise and pharma revenue story for investors. Sally will happily cheer a real cure. She is just noting that the halo and the pitch deck arrived in the same box.

• •Anthropic launched Claude Science on June 30, 2026, a workbench connecting to more than 60 scientific databases with toolkits for genomics, protein structure and chemistry.
• •A central AI assistant acts as a project manager, organizing research projects and delegating tasks to sub-assistants.
• •Anthropic also announced an internal drug discovery program focused on neglected diseases, led by life sciences head Eric Kauderer-Abrams.
• •Claude Science is in beta for Pro, Max, Team and Enterprise subscribers, with funding of up to 30,000 dollars in credits for up to 50 projects, applications open through July 15.
• •It builds on CEO Dario Amodei's goal of compressing life sciences R&D tenfold, the acquisition of Coefficient Bio and the hire of AlphaFold Nobel laureate John Jumper, as Anthropic heads toward a blockbuster IPO.